SetPFPGroupVar.htm
   
SetPProProdListVar.htm

New User? Register Now

Returning User? Sign In

Benefits of registering


login.htm

Visit other Pfizer sites
Search Medical Responses
View an extensive list of Pfizer sites
ppn-vr-sso-links.htm

Share Your Feedback
Product Centers | AROMASIN(R) (exemestane tablets)
 
AROMASIN(R) (exemestane tablets) Indication Statement AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Select a category from the links below. To view an item, click on its title.

Video Presentations | Professional Materials | Slides | Patient Education
Video Presentations

Video AROMASIN MOA

This video animation reveals how AROMASIN works in the treatment of early and advanced breast cancer in postmenopausal women.

VideoThe Intergroup Exemestane Study (IES): Clinical Insights From a Principal Investigator

Dr Stephen Jones, Medical Director of US Oncology Research in Houston, Texas and Director of Breast Cancer Research at the Baylor-Sammons Cancer Center in Dallas, TX, discusses findings from the IES study.

Back to Top


Professional Materials

Broad Range of Efficacy Information SheetBroad Range of Efficacy Information Sheetpdf image

This professional resource provides data that support sequencing to AROMASIN after 2 to 3 years of tamoxifen vs continuing on tamoxifen for a total of 5 years.

Thumbnail photo of Physician Brochure First Resource®Brochurepdf image

This resource provides an overview about First Resource—a reimbursement and patient assistance program provided by Pfizer Oncology to help patients gain access to medicines they need.



Back to Top


Slides

AROMASIN (exemestane) Adjuvant Therapy for Early Stage Breast Cancer After 2 to 3 Years of Tamoxifen
This slide presentation is for educating physicians on the efficacy and safety of AROMASIN in the adjuvant setting.


Back to Top


Patient Education

AROMASIN.comAROMASIN.comAromasin.com

A Web site for patients with information on AROMASIN and a number of tools and resources, including:

  • A Doctor Discussion Guide
  • Tips on managing side effects
  • Patient testimonials

AROMASIN Patient BrochureAROMASIN Patient Brochure (Customize)

This patient brochure manages treatment expectations for those taking AROMASIN and includes information on:

  • Efficacy and what to expect when taking AROMASIN
  • How to take AROMASIN
  • Side effects/safety
  • Frequently asked questions about treatment
  • Real-world patient treatment experience

Treatment JournalTreatment Journal (Customize)

This journal helps patients track their first few months of treatment, helping to facilitate positive patient experience with AROMASIN and encouraging patients to discuss their treatment with their doctor.
Switch QuizSwitch Quiz (Customize)

This leaflet is targeted at tamoxifen patients to help them determine if they may be appropriate for AROMASIN by taking a short quiz and encourages them to speak with their doctor.
SPatient Brochure for Tamoxifen PatientsPatient Brochure for Tamoxifen Patients (Customize)

This patient brochure provides relevant information about AROMASIN and emphasizes the importance of switching to AROMASIN after 2 to 3 years of treatment to complete 5 years of adjuvant treatment.

Back to Top


Visit Patient Education Materials for additional downloadable, printable resources for your patients.

When you click on an item, it will open in a new window.


download Adobe Acrobat Reader In order to view these PDF documents, you must have Adobe Reader installed on your computer. If you do not have Adobe Reader, download it from the Adobe Web site.


Note that the Adobe Web site is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services on that site.

Adobe, the Adobe logo, and Reader are registered trademarks of Adobe Systems Incorporated in the United States and/or other countries.